tradingkey.logo
tradingkey.logo

FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer

ReutersMar 25, 2026 2:59 PM

- US FDA:

  • FDA APPROVES RELACORILANT WITH NAB-PACLITAXEL FOR PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI